SCHEMBL95171

SCHEMBL95171

CCCc1ccc(-c2nnc(C[O])o2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
KMT2A Q03164 3/20 0.46
ALOX12 P18054 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
ALDH1A1 P00352 5/20 0.44
TSHR P16473 3/20 0.44
POLB P06746 2/20 0.44
USP2 O75604 1/20 0.44
NR1H4 Q96RI1 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
HPGD P15428 3/20 0.42
GPR55 Q9Y2T6 1/20 0.42
KDM4E B2RXH2 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090607 0.87 NOTUM (0.49) MAPTKMT2AALOX12NPC1RAB9A
SCHEMBL2968358 0.85 MAPT (0.54) MAPTKMT2AALOX12CA1CA2
SCHEMBL13340753 0.84 MAPT (0.53) MAPTKMT2AALOX12NPC1RAB9A
SCHEMBL95172 0.84 NOTUM (0.60) MAPTKMT2AALOX12CA1CA2
SCHEMBL97042 0.80 KMT2A (0.58) MAPTKMT2AALOX12NPC1RAB9A
SCHEMBL2968360 0.79 MAPT (0.54) MAPTKMT2AALOX12CA1CA2
SCHEMBL12844628 0.78 MAPT (0.47) MAPTKMT2AALOX12NPC1RAB9A
SCHEMBL96804 0.75 NR1H4 (0.65) MAPTNPC1RAB9AALDH1A1TSHR
SCHEMBL12798169 0.75 NPC1 (0.64) MAPTKMT2ANPC1RAB9AALDH1A1
SCHEMBL20619966 0.75 MAPT (0.69) MAPTKMT2AALOX12NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB MAPT 4112/4885KMT2A 1059/4885ALOX12 922/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 MAPT 4773/4885KMT2A 2732/4885ALOX12 839/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 MAPT 4773/4885KMT2A 2732/4885ALOX12 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.